| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
OtisMed Corporation is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeoMend is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A nutritional ingredient manufacturer, Kemin is a privately held corporation, founded in 1961 by R.W. and Mary Nelson.
div#n2-ss-2{width:1200px;}div#n2-ss-2 .n2-ss-slider-1{position:relative;}div#n2-ss-2 .n2-ss-slider-background-video-container{position:absolute;left:0;top:0;width:100%;height:100%;overflow:hidden;}div#n2-ss-2 .n2-ss-slider-2{position:relative;overflow:...